Skip to content

Based on PD-1/PD-L Signal Pathway to Discuss the Effect of Shendi Granules on Immune imbalance in chronic glomerulonephritis patients with spleen and kidney deficiency syndrome

Based on PD-1/PD-L Signal Pathway to Discuss the Effect of Shendi Granules on Immune imbalance in chronic glomerulonephritis patients with spleen and kidney deficiency syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014507
Enrollment
Unknown
Registered
2018-01-17
Start date
2018-01-18
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic glomerulonephritis

Interventions

treatment group:conventional therapy+ Shendi Granules
control group:conventional therapy

Sponsors

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. age 18~70 years old; 2. in accordance with the above standards for the diagnosis of Western medicine and the standard of TCM syndrome differentiation; 3. 24 hour urine protein 2.0g/d; 4. eGFR > 60ml/min; 5. application of angiotensin-converting enzyme inhibitors (ACEI) / angiotensin II receptor antagonist (ARB) and amlodipine treatment has been 2 weeks washout period, or before entering the group without the use of ACEI/ARB (except Valsartan Capsules), amlodipine besylate; 6. based antihypertensive therapy, drugs not including ACEI/ARB (except Valsartan Capsules), amlodipine, blood pressure less than 140/90mmHg.

Exclusion criteria

Exclusion criteria: 1. combined with other autoimmune diseases and malignant tumors; 2. severe arrhythmia, severe heart failure, NYHA grade III and above (evidence of grade III and IV of New York Heart Association); 3. severe liver disease, or abnormal liver function (ALT > 1.5 times as normal); 4. patients with hematopoietic dysfunction, bleeding tendency and hemorrhagic disease; 5. secondary and hereditary renal diseases; 6. patients with deficiency of immune function; 7. the history of drug abuse and alcoholism; 8. the use of immunosuppressants is being used; 9. with severe gastrointestinal symptoms; 10. pregnant women and breast-feeding women.

Design outcomes

Primary

MeasureTime frame
24 hour urine protein quantitation;routine urine test;TCM syndrome score;

Secondary

MeasureTime frame
ACR/TCR of urine;serum creatinine;serum creatinine;blood fat;

Countries

China

Contacts

Public ContactYiping Wang

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

wypwyp54@aliyun.com+86 13075580986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026